Company Encyclopedia
View More
name
Lummy
300006.SZ
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. The company provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. Chongqing Lummy Pharmaceutical Co., Ltd.
3.159 T
300006.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking195/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-5.51%D
    • Profit Margin-13.92%D
    • Gross Margin56.60%B
  • Growth ScoreE
    • Revenue YoY-9.98%D
    • Net Profit YoY-659.76%E
    • Total Assets YoY-9.04%E
    • Net Assets YoY-12.12%E
  • Cash ScoreE
    • Cash Flow Margin-718.53%E
    • OCF YoY-9.98%D
  • Operating ScoreD
    • Turnover0.27D
  • Debt ScoreB
    • Gearing Ratio32.95%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Lummy: Product Nicorandil tablets intend to be selected for the 11th batch of national drug procurement

    Lummy announced that the company participated in the bidding for the 11th batch of national centralized drug procurement, with the product Nicorandil tablets expected to be selected, with a proposed selection price of 2.95 yuan/box. The proposed selection quantity and the provinces to be supplied will be subject to final data. This product obtained its registration certificate in 2025 and has not yet been sold as of now. If the procurement contract is signed and implemented subsequently, it will promote product sales and market expansion, enhancing brand influence. However, there are uncertainties regarding the signing of the procurement contract and other subsequent matters

    Zhitong·
    SZ
    300006
    -0.20%
    Zhitong·
    SZ
    300006
    -0.20%

    Lummy Pharmaceuticals released its performance for the first three quarters, with a net loss attributable to the parent company of 45.9172 million yuan

    According to the Zhitong Finance APP, Lummy released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 581 million yuan, a year-on-year decrease of 4.06%. The net loss attributable to shareholders of the listed company was 45.9172 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 48.379 million yuan. The basic loss per share was 0.0435 yuan

    Zhitong·
    SZ
    300006
    -0.20%
    Zhitong·
    SZ
    300006
    -0.20%

    The pharmaceutical sector fluctuates and strengthens, ASK PHARM hits the limit up

    The pharmaceutical sector fluctuated and strengthened, with ASK PHARM hitting the limit up, SUNFLOWER rising over 13%, and Cosunter, Xinlitai, Lummy, and INNOCARE among the top gainers

    Zhitong·
    SZ
    002755
    +0.29%
    SZ
    300111
    +0.69%
    SZ
    300436
    +0.09%
    Zhitong·
    SZ
    002755
    +0.29%
    SZ
    300111
    +0.69%
    SZ
    300436
    +0.09%

    Lummy obtained two drug registration certificates

    According to the Zhitong Finance APP, Lummy announced that the company has received the Drug Registration Certificates for two medications: Nicorandil Tablets (Specification: 5mg) and Ketorolac Tromethamine Injection (Specification: 1ml: 30mg) approved by the National Medical Products Administration. The announcement indicates that Nicorandil Tablets are used for the treatment of angina pectoris. Ketorolac Tromethamine Injection is suitable for the short-term treatment of moderate to severe acute postoperative pain

    Zhitong·
    SZ
    300006
    -0.20%
    Zhitong·
    SZ
    300006
    -0.20%

    Lummy: The equity structure of the indirect controlling shareholder is expected to change

    Lummy announced that its controlling shareholder, Zhongheng Group, received a notice from its indirect controlling shareholder, Guangtou Group, stating that there will be a change in Guangtou Group's equity structure. The Guangxi State-owned Assets Supervision and Administration Commission will transfer its 33% stake in Guangtou Group to Guangxi Guokong Group without compensation. After this change, Zhongheng Group will still be the controlling shareholder, and the Guangxi State-owned Assets Supervision and Administration Commission will remain the actual controller, with no substantial impact on the company's operations and production activities

    Zhitong·
    SZ
    300006
    -0.20%
    Zhitong·
    SZ
    300006
    -0.20%
    © 2025 Longbridge｜Disclaimer